Technical Analysis for NKTX - Nkarta, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 20 DMA | Bearish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Crossed Above 20 DMA | Bullish | -6.29% | |
Earnings Movers | Other | -6.29% | |
Wide Bands | Range Expansion | -6.29% | |
Gapped Up | Strength | -6.29% | |
Fell Below 20 DMA | Bearish | 0.18% | |
MACD Bearish Signal Line Cross | Bearish | 0.18% | |
Earnings Movers | Other | 0.18% | |
Wide Bands | Range Expansion | 0.18% |
Alert | Time |
---|---|
Fell Below Previous Day's Low | about 20 hours ago |
Down 10% | about 20 hours ago |
Down 1 ATR | about 20 hours ago |
Down 5% | about 20 hours ago |
Down 3% | about 20 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/14/2024
Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Biology Immune System Immunotherapy Cancer Treatment Tumor Lymphoma Gene Therapy Virotherapy Chimeric Antigen Receptor T Cell Natural Killer Cell Chimeric Antigen Receptor Therapies For Cancer Antigen CD19 Tumor Cell
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Biology Immune System Immunotherapy Cancer Treatment Tumor Lymphoma Gene Therapy Virotherapy Chimeric Antigen Receptor T Cell Natural Killer Cell Chimeric Antigen Receptor Therapies For Cancer Antigen CD19 Tumor Cell
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 16.24 |
52 Week Low | 1.28 |
Average Volume | 2,184,222 |
200-Day Moving Average | 4.59 |
50-Day Moving Average | 10.54 |
20-Day Moving Average | 12.15 |
10-Day Moving Average | 13.34 |
Average True Range | 1.21 |
RSI (14) | 47.92 |
ADX | 39.73 |
+DI | 24.25 |
-DI | 21.61 |
Chandelier Exit (Long, 3 ATRs) | 12.60 |
Chandelier Exit (Short, 3 ATRs) | 13.04 |
Upper Bollinger Bands | 15.73 |
Lower Bollinger Band | 8.57 |
Percent B (%b) | 0.4 |
BandWidth | 58.89 |
MACD Line | 0.68 |
MACD Signal Line | 1.01 |
MACD Histogram | -0.3222 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 13.44 | ||||
Resistance 3 (R3) | 13.49 | 12.87 | 13.10 | ||
Resistance 2 (R2) | 12.87 | 12.35 | 12.84 | 12.99 | |
Resistance 1 (R1) | 12.13 | 12.03 | 11.82 | 12.08 | 12.87 |
Pivot Point | 11.51 | 11.51 | 11.35 | 11.48 | 11.51 |
Support 1 (S1) | 10.77 | 10.99 | 10.46 | 10.72 | 9.93 |
Support 2 (S2) | 10.15 | 10.67 | 10.12 | 9.81 | |
Support 3 (S3) | 9.41 | 10.15 | 9.70 | ||
Support 4 (S4) | 9.36 |